Clinical Trial Update: ALK27-001: A Study of Trospium Inhalation Powder (TrIP)Administered to Subjects With COPD [Phase 2]

View source ↗

Summary

Phase 2 study of Trospium Inhalation Powder (TrIP) in subjects with chronic obstructive pulmonary disease has completed. Results were posted in May 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Trospium Inhalation Powder (TrIP) (trospium chloride)

Snippet

Sponsor: Alkermes, Inc. | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Status: COMPLETED | Results posted: 2011-05-10